United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

3:30pm GMT
Change (% chg)

$0.01 (+0.03%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron:Habib Dable named president and ceo
Tuesday, 27 Sep 2016 

Acceleron Pharma Inc : Acceleron announces retirement of John Knopf as president and ceo; Habib Dable named as successor . Habib Dable appointed as president and ceo .Acceleron Pharma Inc says Habib Dable will assume ceo role effective December 1, 2016.  Full Article

Acceleron Pharma Q2 loss per share $0.59
Thursday, 4 Aug 2016 

Acceleron Pharma Inc : Acceleron Pharma reports second quarter 2016 financial and operational results . Q2 loss per share $0.59 .Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces ACE-083 phase 1 results
Friday, 8 Jul 2016 

Acceleron Pharma Inc : Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases . ACE-083 increased muscle volume of tibialis anterior muscle by 8.9% in healthy volunteers .Acceleron intends to advance ACE-083 into a phase 2 clinical trial in patients with FSHD in second half of 2016..  Full Article

Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels
Friday, 10 Jun 2016 

Acceleron Pharma Inc : Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association . Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden . Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels .Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study.  Full Article

Acceleron Announces Proposed Public Offering of Common Stock
Monday, 4 Jan 2016 

Acceleron Pharma Inc:intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering.As part of this offering Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the number of shares sold.All of the shares in the offering are to be sold by Acceleron.Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are acting as joint book-running managers for the offering.JMP Securities is acting as the lead manager.Acceleron intends to use net proceeds from the offering to conduct clinical trials and associated activities in connection with ACE-083 and Acceleron's other potential therapeutic candidates, including antibodies and proteins from Acceleron's IntelliTrap platform.to further expand Acceleron's research and development efforts, and for general and administrative expenses, potential future development programs, capital expenditures and working capital and other general corporate purposes.  Full Article

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions